<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02591771</url>
  </required_header>
  <id_info>
    <org_study_id>AltShock</org_study_id>
    <nct_id>NCT02591771</nct_id>
  </id_info>
  <brief_title>Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock</brief_title>
  <official_title>Phase II Clinical Trial for a Stepwise Progression in the Treatment of Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niguarda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Niguarda Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of i.v. adrenaline infusion as&#xD;
      an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion&#xD;
      monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock,&#xD;
      including ventricular mechanical support.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiogenic shock is characterized by a decrease in cardiac output and increased ventricular&#xD;
      pressures, with subsequent symptoms and signs of systemic hypoperfusion. In spite of the&#xD;
      multiple pharmacological chances the in-hospital mortality rate is still very high (around&#xD;
      60% of patients) and nowadays there is not a therapeutic &quot;reference standard&quot; associated with&#xD;
      an improved survival at short and midterm. Adrenaline is a mainstay of resuscitation therapy&#xD;
      during cardiopulmonary arrest, however, it is not clear whether this inotrope actually&#xD;
      facilitates an improvement in patients affected by cardiogenic shock. In a small local&#xD;
      evidence-based experience, contrary to current opinion, it has been shown that adrenaline may&#xD;
      still have a role in the treatment of patients with low output state. This phase II study&#xD;
      tests the hypothesis that adrenaline infusion, integrated in a multistep approach at&#xD;
      increasing intensity, can be a valid support with limited side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 25, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at 60 days</measure>
    <time_frame>60 days</time_frame>
    <description>number of successes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of i.v. infusion with adrenaline</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adrenaline maximum dose</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to weaning from beginning with pharmacological therapy and mechanical ventricular support</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of medical staff support and nursing-care hours dedicated to each patient</measure>
    <time_frame>Within patient hospitalization, each day from day 1 to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Membrane oxygenation</measure>
    <time_frame>60 days</time_frame>
    <description>Escalation to venoarterial extracorporeal membrane oxygenation (VA-ECMO)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>adrenaline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adrenaline</intervention_name>
    <description>i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support</description>
    <arm_group_label>adrenaline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age ≥ 18 and &lt; 75, men and women;&#xD;
&#xD;
          -  1) SBP &lt; 90mmHg or MAP &lt; 60 mmHg, after an appropriate fluid challenge if there is no&#xD;
             sign of overt fluid overload; OR 2) need of vasoactive agents to maintain SBP &gt; 90&#xD;
             mmHg or MAP &gt; 60 mmHg.&#xD;
&#xD;
          -  Pre-existing diagnosis of heart failure with reduced ejection fraction (left ventricle&#xD;
             systolic function ≤35%).&#xD;
&#xD;
          -  Moreover, eligible patients have to fit at least ONE of the following criteria/items&#xD;
             of overt hypoperfusion: mixed venous oxygen saturation &lt; 60%; arterial lactates &gt; 2&#xD;
             mmol/L; oliguria &lt; 0.5 ml/Kg/h for at least 6 hours.&#xD;
&#xD;
          -  Eligible patients shouldn't have contraindications to HRT.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Cardiogenic shock symptoms beyond 6 hours.&#xD;
&#xD;
          -  Septic shock with evident septic focus.&#xD;
&#xD;
          -  Cardiogenic shock due to acute myocardial infarction.&#xD;
&#xD;
          -  Cardiogenic shock due to acute myocarditis.&#xD;
&#xD;
          -  Cardiogenic shock due to pulmonary thromboembolism.&#xD;
&#xD;
          -  Reiterating major arrhythmias: VT or VF or AF, with ventricular rate &gt; 160 bpm.&#xD;
&#xD;
          -  Severe aortic valve disease.&#xD;
&#xD;
          -  Obstructive hypertrophic cardiomyopathy or constrictive pericarditis or severe heart&#xD;
             failure due to congenital heart disease&#xD;
&#xD;
          -  Severe peripheral vascular disease that contraindicates mechanical support insertion.&#xD;
&#xD;
          -  Cardiogenic shock secondary to either cardiac or non-cardiac surgery.&#xD;
&#xD;
          -  Post-cardiac arrest syndrome following out of hospital cardiac arrest&#xD;
&#xD;
          -  Comorbidities with ominous prognosis (life expectancy &lt; 1 year).&#xD;
&#xD;
          -  End-stage organ failure.&#xD;
&#xD;
          -  Pregnant, lactating or subjects planning pregnancy during the course of the trial.&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participants at risk because of participation in the trial, or may&#xD;
             influence the result of the trial, or the participant's ability to participate in the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Niguarda Hospital</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Morici N, Oliva F, Ajello S, Stucchi M, Sacco A, Cipriani MG, De Bonis M, Garascia A, Gagliardone MP, Melisurgo G, Russo CF, La Vecchia C, Frigerio M, Pappalardo F. Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial. Am Heart J. 2018 Oct;204:196-201. doi: 10.1016/j.ahj.2018.07.009. Epub 2018 Jul 20.</citation>
    <PMID>30100052</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 11, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adrenaline</keyword>
  <keyword>Extra Corporeal Life Support</keyword>
  <keyword>Inotropes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

